HKHaydar Soydaner Karakuş

Haydar Soydaner Karakuş

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Haydar Soydaner Karakuş has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Gene Expression Profiling of EGFR , FGFR2 , PIK3CA , PTEN , SMAD4 , STK11 , and TP53 in Cell‐Free RNA From Exhaled Breath Condensate: Diagnostic, Prognostic, and Therapeutic Implications in Advanced Lung Adenocarcinoma

    by Sabina Latifova, Uygar Genis, Haydar Soydaner Karakus, Korcan Korba, Su Ozgur, Ceyda Aldag, Tuncay Goksel, Levent Pelit, Cumhur Gunduz, Asli Tetik Vardarli

    Background: Advanced non‐small cell lung cancer (NSCLC), particularly lung adenocarcinoma, remains a leading cause of cancer‐related mortality. Although molecular profiling has improved disease stratification, most biomarker assays rely on invasive tissue sampling. Exhaled breath condensate (EBC) is an attractive non‐invasive biofluid that may provide clinically relevant molecular information. This study evaluated whether cell‐free RNA (cfRNA) obtained from EBC can capture diagnostically and prognostically informative gene‐expression changes in advanced lung adenocarcinoma. Methods: In this prospective study, 40 patients with histologically confirmed stage IIIB–IV lung adenocarcinoma and 20 healthy controls were enrolled. EBC samples were collected from all participants, and plasma samples were obtained from a subgroup of 10 patients and 10 controls. Expression of EGFR, FGFR2, PIK3CA, PTEN, SMAD4, STK11, and TP53 was quantified by RT‐qPCR and normalized to GAPDH using the 2 −ΔΔCT method. Receiver operating characteristic (ROC) analysis, correlation testing, and Kaplan–Meier survival analysis were performed. Results: The most clinically relevant findings were observed for PIK3CA , FGFR2 , and EGFR . In EBC, PIK3CA emerged as the only gene with significant diagnostic performance for distinguishing patients from healthy controls (AUC = 0.8522; sensitivity 81.58%; specificity 76.92%). In survival analyses, high FGFR2 and high PIK3CA expression were associated with significantly shorter overall survival, supporting their prognostic relevance. In treatment‐stratified analysis, low EGFR expression was associated with longer survival in patients receiving chemotherapy alone, suggesting potential predictive value in this subgroup. In plasma, PIK3CA was upregulated approximately five‐fold, whereas EGFR was downregulated approximately five‐fold. Notably, EGFR expression showed a strong positive correlation between EBC and plasma ( R 2 = 0.7849, p = 0.0006), indicating cross‐matrix consistency for this marker. By contrast, alterations in PTEN , TP53 , and SMAD4 should be considered exploratory, as they showed differential expression but lacked comparable diagnostic, prognostic, or treatment‐associated strength. Conclusions: EBC‐based cfRNA profiling provides a feasible, non‐invasive approach for molecular characterization of advanced lung adenocarcinoma. Among the genes examined, PIK3CA showed the strongest diagnostic signal, FGFR2 demonstrated prognostic significance, and EGFR showed the clearest cross‐sample concordance and treatment‐associated relevance. Larger independent validation studies are required before clinical implementation.

  • Open Access

    Update: The New 9th Edition TNM Classification for Lung Cancer Is Now in Use

    by Yusuf Kahya, Feride Marım, Gökçen Ömeroğlu Şimşek, Haydar Soydaner Karakuş, Sevin Başer Öncel, Müge Meltem Tor, Tuncay Göksel

    Update: The New 9th Edition TNM Classification for Lung Cancer Is Now in Use - Thoracic Research and Practice


  • Open Access

    Investigation of Epidermal Growth Factor Receptor Pathway Related, Exosomal miRNAs in Non-Small Cell Lung Cancer Cases

    by Altuğ Koç, Asım Leblebici, Haydar Soydaner Karakuş, Ceyda Aldağ, Kadri Murat Erdoğan, Merve Saka Güvenç, Su Özgür, Tuncay Göksel, Yasemin Başbınar

    Background and Purpose: Recently, the “Epidermal Growth Factor Receptor” gene and its related pathways are potential targets in precision medicine for “Non-Small Cell Lung Cancer” cases. The presented study is a proof of concept study, which utilizes exosomal miRNAs as an easy and cheap liquid biopsy approach. We aim to investigate, 4 exosomal miRNAs: miR-30b, miR-30c, miR-221-3p, miR-22-3p; and miR-1288 as control. They are defined in the literature previously. Methods: Thirty-six samples from distinct Non-Small Cell Lung Cancer cases are analyzed. Exosomes are extracted from the plasma of the patients; miRNA isolation, cDNA synthesis, and real-time quantitative polymerase chain reactions are done and ∆/∆ Ct method is used for relative quantification. Results: The control miR1288 is expressed in all of the samples except one. The two miRNA targets miR-30c and miR-22-3p produced polymerase chain reaction curves successfully. The remaining two miRNAs (miR-30b, miR-221-3p) produce weak polymerase chain reaction curves. Conclusion: miR-30b, miR-221-3p, miR-30c, and miR-22-3p are reported to be associated with lung cancer previously, but they have not been studied in a patient series before. In our study, the exosomal miR-30c, and miR-22-3p are successfully derived from the plasma of cancer cases and they could be potential biomarkers.

  • Open Access

    Symptom clusters in patients with lung cancer patients receiving chemotherapy

    by Özlem Uğur, Hatice Mert, Ezgi Karadağ, Haydar Soydaner Karakuş, Tugba Yavuzşen, İlHan Öztop, Canan Demi̇r Barutcu

    Aim: The aim was to identify symptoms experienced by patients with lung cancer who had received chemotherapy and to determine the symptom clusters.Materials and Methods: This was a descriptive and cross-sectional study. A Patient Presentation Form, the ECOG Performance Scale, and the Memorial Symptom Assessment Scale were used. The data were collected between September 2016 and June 2017. The sample of the study consisted of 100 patients who met the selection criteria.Results: When the prevalence of the symptoms experienced by the patients was examined, the most common complaints were lack of energy (82%), loss of appetite (71%), change in taste of food (62%), anxiety and feeling irritable (69%). The most common symptoms were weakness (8%), loss of appetite (14%), anxiety (20%) and feeling sad (28%).Conclusion: When the occurrence and severity ratings were examined, the symptoms could be placed into five groups: the gastrointestinal system cluster, the psychology cluster, the respiratory cluster, the neurology cluster, and the cluster of skin changes. The symptoms of lung cancer patients interact with each other and should be managed with appropriate interventions. Moreover, health professionals’ awareness of symptom management should be improved.


  • Magnetic Catheter Navigation Systems

    by Özge Akbülbül, Mert Şener, Gökhan Özdemi̇r, Aylin Şendemi̇r, Ece Bayir, Tuncay Goksel, Haydar Soydaner Karakuş, Mutlu Boztepe, Levent Çeti̇n, Gökmen Atakan Türkmen, et al.

    Son 10 yılda biyopsi ve tanı işlemleri esnasında doktor vasıtasıyla manuel ve robotik olarak gerçekleştirilen endoskopi, kolonoskopi, bronkoskopi gibi işlemlerde oluşabilecek komplikasyonları en aza indirmeye yarayacak sistemlerin üzerine çalışılmaya başlanmıştır. Bu sistemlerin en önemli özelliği yönlendirilecek kateterin manyetik özelliğe sahip olması ve elektromanyetik sistemler ile kateterin temassız bir şekilde yönlendirilmesidir. Bunun yanı sıra tedaviye yönelik başka işlemler için de manyetik özelliğe sahip kapsül, robot, ilaç taşıma sistemleri vb. araçlar geliştirilmektedir. Bu araçların yönlendirilmesi de bahsedilen sistemler aracılığıyla temassız bir şekilde gerçekleştirilebilmektedir. Bu çalışmada temassız yönlendirmeyi sağlayan manyetik kateter navigasyon sistemleri hakkında bilgi verilmektedir.

  • Prevalence and Seasonal Distribution of Respiratory Viruses in Patients with Acute Respiratory Tract Infections, 2002-2014

    by Candan Çi̇çEk, Ayşe ARSLAN, Haydar Soydaner Karakuş, Mehmet Yalaz, Eylem Ulaş SAZ, Hüsnü Pullukçu, Gürsel Çok

    <%=header_description %> <%=header_description %>


  • Hypersensitivity to chemotherapeutics: a cross sectional study with 35 desensitisations

    by Ozlem Goksel, Tuncay Goksel, Gursel Cok, Haydar Karakus, Feza Bacakoglu, Erdem Goker, Ruchan Uslu, Munevver Erdinc

    Chemotherapy is one of the main treatments for lung cancer, and in these patients, discontinuation of treatment due to uncontrollable hypersensitivity reactions (HSRs) is an important problem. To determine the frequency of HSRs during chemotherapy and to review current approaches. We did a cross sectional study in patients undergoing chemotherapy for lung cancer in a reference chemotherapy unit from January 2012 to January 2013. Patients who developed immediate-HSRs or delayed-HSRs to chemotherapeutics and gave consent were included into study. The effectiveness of a standardised 12-step “rapid drug desensitisation” (RDD) procedure was investigated in patients with immediate-HSRs. In total, 1,099 cycles of chemotherapy were administered to 292 patients in 1 year. We observed ten HSRs, during ten cycles in ten patients (~3 % of the patients). Two HSRs were delayed-type, eight were immediate-type at grade 1–3. Of those with immediate-type HSR, five patients with grade 2–3, and additional two referred patients with grade 4 HSRs were successfully given their culprit drug in 35 cycles of chemotherapy with 12-step or modified 20-step RDD protocol. HSRs to chemotherapeutics are not so rare. Premedication alone does not prevent such reactions. The results of RDD treatment look promising for continuing treatment with the culprit chemotherapeutic agent.


  • The role of Tc-99m sestamibi imaging in predicting clinical response to chemotherapy in lung cancer

    by Aysegul Dirlik, Zeynep Burak, Tuneay Goksel, Ruya Erine, Haydar Karakus, Zehra Ozcan, Ali Veral, Mustafa Ozhan